Global active pharmaceutical ingredients (API) market will reach $ 386.2 billion by 2032, growing by 6.4% annually over 2022-2032, driven by rising adoption of biologics in disease management, ...

North America active pharmaceutical ingredients (API) market is projected to grow by 4.8% annually in the forecast period and reach $120.7 billion by 2032, driven by rising adoption of biologics in ...

The stock's fall snapped a three-day winning streak.

AbbVie, Inc. ABBV and Bristol Myers Squibb BMY are leading drugmakers with broad and diverse portfolios and a global footprint. AbbVie is a global, diversified biopharmaceutical company with a ...

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" ...

When blockbuster drugs lose intellectual property protections it can wipe out billions of dollars in revenue for companies ...

CHENNAI: Glenmark Pharma’s licensing pact for its investigational cancer drug ISB 2001 is not just a deal --it’s a turning point in Indian pharma/biotech innova ...

The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory ...

Glenmark's arm IGI Therapeutics signs a $700 million licensing deal with AbbVie for its cancer drug ISB 2001, with potential ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

The cancer cachexia market is expected to witness an expansion across the 7MM, driven by the introduction of innovative therapies, ponsegromab (PF-06946860), S-pindolol benzoate (ACM-001.1) ...